Influence of the exon 3-deleted/full-length growth hormone (GH) receptor polymorphism on the response to Gh replacement therapy in adults with severe GH deficiency

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 2, 2009, Pages 639-644

  Barbosa, Edna J L ^a,b   Palming, Jenny ^a   Glad, Camilla A M ^a   Filipsson, Helena ^a   Koranyi, Josef ^a   Bengtsson, Bengt Åke ^a   Carlsson, Lena M S ^c   Boguszewski, Cesar L ^b   Johannsson, Gudmundur ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE RECEPTOR; SOMATOMEDIN C;

ADULT; ARTICLE; BODY FAT; CONTROLLED STUDY; DNA POLYMORPHISM; EXON; FEMALE; GENETIC ANALYSIS; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

EID: 59749098582     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-0323     Document Type: Article

References (40)

1. Salomon F, Cuneo RC, Hesp R, Sonksen PH 1989 The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 321:1797-1803
2. Jorgensen JO, Pedersen SA, Thuesen L, Jørgensen J, Ingemann-Hansen T, Skakkebaek NE, Christiansen JS 1989 Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1:1221-1225
3. de Boer H, Blok GJ, Popp-Snijders C, Stuurman L, Baxter RC, van der Veen E 1996 Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers. J Clin Endocrinol Metab 81:1371-1377
4. Monson JP 2001 Biochemical markers of individual response to growth hormone replacement in adults. Horm Res 55(Suppl 2):49-54
5. Gibney J, Johannsson G 2004 Long-term monitoring of insulin-like growth factor I in adult growth hormone deficiency: a critical appraisal. Horm Res 62(Suppl 1):66-72
6. Johannsson G, Bjarnason R, Bramnert M, Carlsson LM, Degerblad M, Manhem P, Rośen T, Thorén M, Bengtsson BA 1996 The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH-binding protein, body mass index, age, and gender. J Clin Endocrinol Metab 81:1575-1581
7. Span JP, Pieters GF, Sweep FG, Hermus AR, Smals AG 2001 Gender differences in rhGH-induced changes in body composition in GH-deficient adults. J Clin Endocrinol Metab 86:4161-4165
8. Bengtsson BA, Abs R, Bennmarker H, Monson JP, Feldt-Rasmussen U, Hernberg-Stahl E, Westberg B, Wilton P, Wüster C 1999 The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board. J Clin Endocrinol Metab 84:3929-3935
9. Burman P, Johansson AG, Siegbahn A, Vessby B, Karlsson FA 1997 Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. J Clin Endocrinol Metab 82:550-555
10. Cook DM, Ludlam WH, Cook MB 1999 Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults. J Clin Endocrinol Metab 84:3956-3960
11. Span JP, Pieters GF, Sweep CG, Hermus AR, Smals AG 2000 Gender difference in insulin-like growth factor I response to growth hormone (GH) treatment in GH-deficient adults: role of sex hormone replacement. J Clin Endocrinol Metab 85:1121-1125
12. Dos Santos C, Essioux L, Teinturier C, Tauber M, Goffin V, Bougneres P 2004 A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet 36:720-724
13. Pantel J, Machinis K, Sobrier ML, Duquesnoy P, Goossens M, Amselem S 2000 Species-specific alternative splice mimicry at the growth hormone receptor locus revealed by the lineage of retroelements during primate evolution. J Biol Chem 275:18664-18669
14. Jorge AA, Marchisotti FG, Montenegro LR, Carvalho LR, Mendonca BB, Arnhold IJ 2006 Growth hormone (GH) pharmacogenetics: influence of GH receptor exon 3 retention or deletion on first-year growth response and final height in patients with severe GH deficiency. J Clin Endocrinol Metab 91:1076-1080
15. Räz B, Janner M, Petkovic V, Lochmatter D, Eblé A, Dattani MT, Hindmarsh PC, Flück CE, Mullis PE 2008 Influence of growth hormone (GH) receptor deletion of exon 3 and full-length isoforms on GH response and final height in patients with severe GH deficiency. J Clin Endocrinol Metab 93:974-980
16. Tauber M, Ester W, Auriol F, Molinas C, Fauvel J, Caliebe J, Nugent T, Fryklund L, Ranke MB, Savage MO, Clark AJ, Johnston LB, Hokken-Koelega AC; NESTEG Ggroup 2007 GH responsiveness in a large multinational cohort of SGA children with short stature (NESTEGG) is related to the exon 3 GHR polymorphism. Clin Endocrinol (Oxf) 67:457-461
17. Pilotta A, Mella P, Filisetti M, Felappi B, Prandi E, Parrinello G, Notarangelo LD, Buzi F 2006 Common polymorphisms of the growth hormone (GH) receptor do not correlate with the growth response to exogenous recombinant human GH in GH-deficient children. J Clin Endocrinol Metab 91:1178-1180
18. Blum WF, Machinis K, Shavrikova EP, Keller A, Stobbe H, Pfaeffle RW, Amselem S 2006 The growth response to growth hormone (GH) treatment in children with isolated GH deficiency is independent of the presence of the exon 3-minus isoform of the GH receptor. J Clin Endocrinol Metab 91:4171-4174
19. Carrascosa A, Esteban C, Espadero R, Fernández-Cancio M, Andaluz P, Clemente M, Audí L, Wollmann H, Fryklund L, Parodi L; Spanish SGA Study Group 2006 The d3/fl-growth hormone (GH) receptor polymorphism does not influence the effect of GH treatment (66 microg/kg per day) or the spontaneous growth in short non-GH-deficient small-for-gestational-age children: results from a two-year controlled prospective study in 170 Spanish patients. J Clin Endocrinol Metab 91:3281-3286
20. Carrascosa A, Audi L, Steban C, Fernández-Cancio M, Andaluz P, Gussinyé M, Clemente M, Yeste D, Albisu MA 2008 Growth hormone (GH) dose, but not exon 3-deleted/full-length GH receptor polymorphism genotypes, influences growth response to two-year GH therapy in short small-for- gestational-age children. J Clin Endocrinol Metab 93:147-153
21. Carrascosa A, Audi L, Fernández-Cancio M, Esteban, C, Andaluz, P, Vilaró, E, Clemente M, Yeste D, Albisu MA, Gussinyé M 2008 The exon 3-deleted/ full-length growth hormone receptor polymorphism did not influence growth response to growth hormone therapy over two years in prepubertal short children born at term with adequate weight and length for gestational age. J Clin Endocrinol Metab 93:764-770
22. Landin-Wilhelmsen K, Wilhelmsen L, Lappas G, Rosén T, Lindstedt G, Lundberg PA, Bengtsson BA 1994 Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid and osteocalcin. Clin Endocrinol (Oxf) 41:351-357
23. Svensson J, Johannsson G, Bengtsson BA 1997 Insulin-like growth hormone-deficient adults: relationship to population-based normal values, body composition and insulin tolerance test. Clin Endocrinol (Oxf) 46:579-586
24. Bruce A, Andersson M, Arvidsson B, Isaksson B 1980 Body composition. Prediction of normal body potassium, body water and body fat in adults on the basis of body height, body weight and age. Scand J Clin Lab Invest 40:461-473
25. Audí L, Esteban C, Carrascosa A, Espadero R, Pérez-Arroyo A, Arjona R, Clemente M, Wollmann H, Fryklund L, Parodi LA; Spanish SGA Study Group 2006 Exon 3-deleted/full-length growth hormone receptor polymorphism genotype frequencies in Spanish short small-for- gestational-age (SGA) children and adolescents (n = 247) and in an adult control population (n = 289) show increased fl/fl in short SGA. J Clin Endocrinol Metab 91:5038-5043
26. Brown H, Prescott R 2006 Applied mixed models in medicine. 2nd ed. New York: John Wiley, Sons Ltd.
27. Bougneres P, Goffin V 2007 The growth hormone receptor in growth. Endocrinol Metab Clin North Am 36:1-16
28. van der Klaauw AA, van der Straaten T, Baak-Pablo R, Biermasz NR, Guchelaar HJ, Pereira AM, Smit JW, Romijn JA 2008 Influence of the d3-growth hormone (GH) receptor isoform on short-term and long-term treatment response to GH replacement in GH-deficient adults. J Clin Endocrinol Metab 93:2828-2834
29. Wickelgren RB, Landin KL, Ohlsson C, Carlsson LM 1995 Expression of exon 3-retaining and exon 3-excluding isoforms of the human growth hormone-receptor is regulated in an interindividual, rather than a tissue-specific, manner. J Clin Endocrinol Metab 80:2154-2157
30. Binder G, Baur F, Schweizer R, Ranke MB 2006 The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children. J Clin Endocrinol Metab 91:659-664
31. Binder G, Trebar B, Baur F, Schweizer R, Ranke MB 2008 Homozygosity of the d3-growth hormone receptor polymorphism is associated with a high total effect of GH on growth and a low BMI in girls with Turner syndrome. Clin Endocrinol (Oxf) 68:567-572
32. Sjogren K, Liu JL, Blad K, Skrtic S, Vidal O, Wallenius V, LeRoith D, Törnell J, Isaksson OG, Jansson JO, Ohlsson C 1999 Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci USA 96:7088-7092
33. Vikman K, Isgaard J, Eden S 1991 Growth hormone regulation of insulin-like growth factor-I mRNA in rat adipose tissue and isolated rat adipocytes. J Endocrinol 131:139-145
34. Johannsson G, Rosen T, Bengtsson BA 1997 Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults. Clin Endocrinol (Oxf) 47:571-581
35. Drake WM, Coyte D, Camacho-Hubner C, Jivanji NM, Kaltsas G, Wood DF, Trainer PJ, Grossman AB, Besser GM, Monson JP 1998 Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. J Clin Endocrinol Metab 83:3913-3919
36. Murray RD, Howell SJ, Lisset CA, Shalet SM 2000 Pre-treatment IGF-I level is the major determinant of GH dosage in adult GH deficiency. Clin Endocrinol (Oxf) 52:537-542
37. Johannsson G 2007 Management of adult growth hormone deficiency. Endocrinol Metab Clin North Am 36:203-220
38. Abrahamsen B, Nielsen TL, Hangaard J, Gregersen G, Vahl N, Korsholm L, Hansen TB, Andersen M, Hagen C 2004 Dose-, IGF-I- and sex-dependent changes in lipid profile and body composition during GH replacement therapy in adult onset GH deficiency. Eur J Endocrinol 150:671-679
39. Boguszewski CL, Meister LH, Zaninelli DC, Radominski RB 2005 One year of GH replacement therapy with a fixed low-dose regimen improves body composition, bone mineral density and lipid profile of GH-deficient adults. Eur J Endocrinol 152:67-75
40. Jensen RB, Vielwerth S, Larsen T, Greisen G, Leffers H, Juul A 2007 The presence of the d3-growth hormone receptor polymorphism is negatively associated with fetal growth but positively associated with postnatal growth in healthy subjects. J Clin Endocrinol Metab 92:2758-2763